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Abstract
The mechanisms underlying the association between orthostatic hypotension (OH) 
and cardiovascular disease are unclear. We investigated whether OH is associated 
with circulating cardiovascular risk markers. This was a cross-sectional analysis of 
3857 older, community-dwelling men. “Consensus OH” was defined as a sitting-to-
standing decrease in systolic blood pressure ≥20 mm Hg and/or diastolic blood pres-
sure ≥10 mm Hg that occurred within three minutes of standing. Multiple generalized 
linear regression and logistic models were used to examine the association between 
cardiovascular risk markers and OH. Consensus OH was present in 20.2%, consist-
ing of isolated systolic OH in 12.6%, isolated diastolic OH in 4.6%, and combined 
systolic and diastolic OH in 3.0%. Concentration of von Willebrand factor, a marker 
of endothelial dysfunction, was positively associated with isolated systolic OH (OR 
1.35, 95% CI 1.05-1.73) and combined systolic and diastolic OH (OR 2.27, 95% CI 
1.35-3.83); high circulating phosphate concentration, which may reflect vascular cal-
cification, was associated with isolated diastolic OH (OR 1.53, 95% CI 1.04-2.25) 
and combined systolic and diastolic OH (OR 2.12, 95% CI 1.31-3.44), high-sensitivity 
troponin T, a marker of myocardial injury, was positively associated with isolated di-
astolic OH (OR 1.69, 95% CI 1.07-2.65) and N-terminal pro-brain natriuretic peptide, 
a marker of cardiac stress, was positively associated with combined systolic and di-
astolic OH (OR 2.14, 95% CI 1.14-4.03). In conclusion, OH is associated with some 
cardiovascular risk markers implicated in endothelial dysfunction, vascular calcifica-
tion, myocardial injury, and cardiac stress. Clinicians should consider assessing car-
diovascular risk in patients with OH.
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1  | INTRODUC TION
Orthostatic hypotension (OH) is an age-dependent physical sign1 
that is present in almost one in five community-dwelling adults 
who are aged 60 years or above.2 Mounting observational data 
have emerged over the last two decades suggesting OH increases 
risk of all-cause mortality,3,4 and that it may be an independent 
risk factor for cardiovascular disease, including stroke, heart fail-
ure, atrial fibrillation, and myocardial infarction.4-8 Indeed, OH has 
been associated with subclinical atherosclerotic vascular disease9 
and structural and functional cardiac changes, including left ven-
tricular hypertrophy and diastolic dysfunction.10 However, there is 
no consensus regarding the underlying mechanisms which explain 
how OH results in these pathological changes and increases car-
diovascular risk.
There are limited data examining the association between circu-
lating cardiovascular risk markers and OH. A small, cross-sectional 
analysis has shown OH to be associated with the inflammatory bio-
markers midkine, immunoglobulin-like transcript 3, and regenerat-
ing islet-derived protein 4.11 Another small, cross-sectional analysis 
has shown OH to be associated with increased concentration of von 
Willebrand factor (VWF),12 a glycoprotein involved in hemostasis 
that is implicated in both endothelial dysfunction and activation.13 
In a large, prospective analysis, OH was associated with higher levels 
of high-sensitivity troponin T (hs-troponin T), a marker of myocardial 
injury, and N-terminal pro-brain natriuretic peptide (NT-proBNP), 
a marker of cardiac stress.9 These findings implicate inflammation 
and endothelial dysfunction—both important contributors to ath-
erosclerosis,14,15 a major cause of cardiovascular disease—as well as 
myocardial injury and cardiac stress as mechanisms that may explain 
the association between OH and increased risk of cardiovascular 
disease.
However, there are specific limitations to these studies. Firstly, 
the study showing an association between inflammatory biomarkers 
and OH was in a cohort of less than 300 people, while the study 
showing an association between VWF and OH was in less than 200 
people. Secondly, the study showing an association between OH 
and hs-troponin T and NT-proBNP was done in middle-aged adults, 
in whom OH is approximately five to six times less prevalent than in 
older adults.1,5 Therefore, to further understand how OH increases 
risk of cardiovascular disease in older adults, in whom the burden 
of OH is greatest, we examined the association between OH and 
circulating cardiovascular risk markers implicated in metabolic risk, 
inflammation, endothelial dysfunction, vascular calcification, myo-
cardial injury, and cardiac stress.
2  | METHODS
2.1 | Study population
Study participants were from The British Regional Heart Study, 
which is an ongoing prospective cohort study that initially recruited 
7735 men aged 40-59 from one general practice in each of 24 British 
towns between 1978 and 1980. The sample was socioeconomically 
representative of the population. Participants were predominantly 
(>99%) of white European ethnicity. Sampling methods have been 
described previously.16 Ethical approval was obtained from the 
National Research Ethics Service Committee London.
For the 20th year of follow-up, all surviving men were invited 
for re-examination, which took place between 1998 and 2000. The 
re-examination involved a self-completed questionnaire, about 
lifestyle and medical history, undergoing physical examination and 
venepuncture. There were 4252 men who completed the ques-
tionnaire and underwent physical examination (77% response rate). 
Anthropometric and physiological measurements included height, 
weight, waist and hip circumference, sitting and standing blood pres-
sure, heart rate, forced expiratory volume in one second, and forced 
vital capacity. Specific methods used for data collection have been 
described previously.16,17
Of the 4252 men, 4045 had measurements of biochemistry. From 
this sample, 117 men with prevalent heart failure were excluded be-
cause heart failure is associated with hypertension,18 which itself is 
a major determinant of OH,6,19 and patients with heart failure have 
exceptionally high risk of cardiovascular and all-cause mortality.20 
Of the remainder, 71 participants had incomplete sitting and stand-
ing blood pressure measurements. They were also excluded, leaving 
3857 participants for the purpose of this analysis.
2.2 | Blood pressure measurements
Sitting and standing blood pressure measurements were taken on 
the right arm using an automatic Dinamap 1846SX. The Dinamap 
blood pressure monitor overestimated systolic blood pressure by 
~8 mm Hg compared with the standard mercury sphygmomanome-
ter which was the standard reference instrument for blood pressure 
measurement at the time.21 8 mm Hg was therefore subtracted from 
the raw systolic blood pressure readings. The cuff was sized accord-
ing to arm circumference: between 28 cm and 35 cm and a standard 
adult cuff was used, <28 cm and a small adult cuff was used and 
>35 cm and a large adult cuff was used. The bladder center of the 
cuff was aligned over the brachial artery. Participants were asked to 
rest their arm on the examination table, such that the upper arm was 
at chest level, for sitting measurements.
The Dinamap was set to take repeated measurements at one 
minute intervals. Four consecutive blood pressure measurements 
were taken: two sitting followed by two standing. Participants had 
not been seated nor supine for a prescribed duration prior to the 
first measurement. The participant was asked to stand after the sec-
ond sitting measurement was completed. The first standing blood 
pressure measurement began within one minute of the participant 
standing, while the second standing blood pressure measurement 
began after one minute of standing. The interval between the start 
of the first sitting measurement and the completion of the second 
standing measurement was 3.5 minutes.
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2.3 | Definition of OH
“Consensus OH” was defined as a decrease in either systolic blood 
pressure ≥20 mm Hg or diastolic blood pressure ≥10 mm Hg, or both, 
that occurred between either the first or second standing blood 
pressure measurements and the mean of the two sitting blood pres-
sure measurements. These specific decreases in blood pressure on 
standing to define OH are endorsed by the American Autonomic 
Society, the European Federation of Autonomic Societies, the 
Autonomic Research Group of the World Federation of Neurology, 
and the Autonomic Disorders section of the American Academy 
of Neurology and described in their consensus statement.22 In ad-
dition, a second classification distinguished subtypes within this 
group. If the decrease only affected systolic blood pressure, this was 
classified as “isolated systolic OH.” If the decrease only affected di-
astolic blood pressure, this was classified as “isolated diastolic OH.” 
If the decrease affected both systolic and diastolic blood pressure, 
this was classified as “combined systolic and diastolic OH.” We ex-
amined the subtypes comprising consensus OH because of evidence 
suggesting the individual components of OH are of different prog-
nostic value: The systolic component appears more predictive of 
stroke and the diastolic component more predictive of myocardial 
infarction, for example.23
2.4 | Measurement of blood markers
At the physical examination, a fasting blood sample was taken for 
laboratory measurements of hematology and biochemistry, includ-
ing total cholesterol, low-density lipoprotein (LDL), high-density li-
poprotein (HDL), triglycerides, glucose, urate, phosphate, fibrinogen, 
von Willebrand Factor (VWF), D-dimer, c-reactive protein (CRP), 
interleukin-6 (IL-6), high-sensitivity troponin T (hs-troponin T), and 
N-terminal pro-brain natriuretic peptide (NT-proBNP). We chose to 
examine these markers in this study because they are implicated in 
cardiometabolic risk, hemostatis and endothelial dysfunction, vas-
cular calcification, myocardial injury, and cardiac stress, mechanisms 
that may, in part, explain the association between OH and cardio-
vascular outcomes.9,11,12 Two extreme outliers—an NT-proBNP of 
35 000 pg/mL and hs-troponin T of 1301 pg/mL—were set to miss-
ing. Details of specific measurement methods have been described 
previously.24-31
2.5 | Statistical methods
Statistical analyses were performed using SAS 9.4. Continuous 
variables that were skewed were log-transformed to approximate 
normality for parametric tests. Skewed variables were CRP, IL-6, 
D-dimer, fibrinogen, glucose, triglycerides, NT-proBNP, and hs-tro-
ponin T. Hypothesis testing was first applied to mean unadjusted 
biomarker values in univariate generalized linear regression analy-
ses. Where statistically significant associations, as per Bonferroni 
adjustment (P < .05/14 tested markers), arose from this analysis, 
these biomarkers were selected for further analyses in both multi-
ple generalized linear and logistic models. For the logistic analyses, 
the biomarkers (independent variable) were grouped into tertiles to 
examine whether elevated levels (top tertile vs bottom tertile) were 
associated with increased odds of OH (dependent variable).
The multiple linear, and logistic, regression models were adjusted 
for age, body mass index, mean sitting systolic blood pressure, rest-
ing pulse, total cholesterol, smoking status (never smoked, ex-smoker 
for 0-15 years, ex-smoker for >15 years, and current smoker), alcohol 
use (0-15 units per week and >16 units per week), physical activity 
(inactive or not inactive), social class (manual or non-manual) and the 
presence of prevalent stroke, myocardial infarction, atrial fibrillation, 
diabetes, chronic kidney disease (CKD), chronic obstructive pulmo-
nary disease (COPD), and current antihypertensive medication use. 
CKD was defined as an estimated glomerular filtration rate (eGFR) 
<60 mL/min/1.73 m2, as estimated from serum creatinine using the 
Modification of Diet in Renal Disease equation.32 Hypertension was 
defined as mean sitting systolic blood pressure ≥140 mm Hg and/or 
mean sitting diastolic blood pressure ≥90 mm Hg (as per the 2018 
European Society of Cardiology-European Society of Hypertension 
and 2019 National Institute for Health and Care Excellence guide-
lines33) and/or antihypertensive medication use. Antihypertensive 
medications were defined as use of any antihypertensive medica-
tion as per British National Formulary (version 38) code 3.1. COPD 
was defined as a forced expiratory volume in one second to forced 
vital capacity ratio of <0.7. Atrial fibrillation was defined according 
to Minnesota codes 8.3.1 and 8.3.3.
Case definitions were obtained from primary care record reviews 
and have been reported previously.17 Methods of measurement and 
classification for measures of lipids, lung function, smoking status, 
physical activity, alcohol intake, and social class have also been re-
ported previously.34,35
A sensitivity analysis was done by excluding participants with 
prevalent stroke and myocardial infarction (n = 352).
3  | RESULTS
3.1 | Prevalence and baseline characteristics
Of the 3857 participants (mean age 68.6 years, standard deviation 
5.5 years), 778 men (20.2%) had consensus OH. Among these, 485 
(12.6%) had isolated systolic OH, 177 (4.6%) had isolated diastolic 
OH, and 116 (3.0%) had both systolic and diastolic OH. Only 10.3% 
of participants with consensus OH were breathless or felt faint 
within three minutes of standing.
Consensus OH was positively associated with age, sitting sys-
tolic blood pressure, sitting diastolic blood pressure, heart rate, 
and resting pulse ≥90 beats per minute. It was not associated with 
smoking status or alcohol consumption. There were differences in 
the distribution of baseline characteristics across the components 
of OH: Heart rate was associated with isolated diastolic OH, but not 
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isolated systolic OH, while BMI was associated with isolated systolic 
OH, but not isolated diastolic OH, for example (Table 1).
3.2 | Co-morbid conditions
Consensus OH was associated with increased odds of prevalent 
CKD, COPD, antihypertensive medication use, and hypertension 
(Table 2). The co-morbidities were differentially distributed among 
the components of OH. COPD was statistically significantly associ-
ated with isolated systolic OH, but not isolated diastolic OH, while 
atrial fibrillation was associated with isolated diastolic OH, but not 
isolated systolic OH. With the exception of COPD and CKD, the 
co-morbidities appeared to cluster with the diastolic component 
of OH.
3.3 | Blood markers
In univariate linear regression analyses, consensus OH was as-
sociated with higher levels of phosphate, IL-6, VWF, D-dimer, 
NT-proBNP, and hs-troponin T. Total cholesterol, LDL, HDL, triglyc-
erides, glucose, urate, fibrinogen, and CRP were not statistically 
significantly associated with consensus OH (Table 3). The markers 
which were statistically significantly associated with OH were se-
lected for multiple generalized linear regression, and logistic regres-
sion, analyses in relation to the systolic and diastolic components of 
OH. In the multiple linear regression analyses (Table 4), VWF was 
associated with isolated systolic OH; phosphate was associated with 
isolated diastolic OH, and combined systolic and diastolic OH and 
NT-proBNP was associated with combined systolic and diastolic OH. 
These associations remained robust in a sensitivity analysis, in which 
TA B L E  1   Baseline characteristics of the study population
No OH
(n = 3079)
COH
(n = 778)
P
ISOH
(n = 485)
P
IDOH
(n = 177)
P
SDOH
(n = 116)
PMean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Age, years 68.4 (5.47) 69.5 (5.50) <.0001 69.4 (5.39) .0002 69.4 (5.65) .0229 70.0 (5.78) .0016
Body mass 
index, kg/m2
26.9 (3.61) 26.6 (3.68) .0527 26.2 (3.58) <.0001 27.4 (3.78) .0609 27.2 (3.72) .3325
Waist 
Circumference, 
cm
97.0 (10.23) 97.0 (10.56) .9652 95.8 (10.45) .0182 99.0 (10.23) .0108 98.8 (10.89) .0737
Sitting systolic 
blood pressure, 
mm Hg
146.6 (23.45) 160.6 (23.90) <.0001 159.1 (22.84) <.0001 159.0 (22.36) <.0001 169.6 (28.35) <.0001
Sitting diastolic 
blood pressure, 
mm Hg
84.3 (10.70) 89.4 (12.17) <.0001 86.3 (11.26) .0002 93.8 (11.55) <.0001 95.3 (12.61) <.0001
Heart ratea , 
beats per 
minute
65 (11.68) 66 (12.49) .0045 66 (13.31) .3705 67 (13.78) .0380 69 (13.50) .0003
Arm 
circumference, 
cm
30.4 (2.77) 30.0 (2.76) .0001 29.9 (2.69) <.0001 30.2 (2.90) .2211 30.3 (2.82) .6191
% % P % P % P % P
Current smokers 12.70 14.00 .3404 15.26 0.1245 7.91 .0622 18.10 .0921
Moderate to heavy alcohol 
consumption
19.89 18.85 .5183 18.70 0.5441 20.69 .7968 16.67 .3976
Physically inactive 32.86 37.05 .0308 35.06 0.3497 38.73 .112 42.73 .0320
Manual Social Class 50.50 52.45 .3323 51.55 0.6683 59.43 .0222 45.69 .3093
Resting tachycardiaa  (heart 
rate ≥ 90 beats per minute)
3.13 5.39 .0034 5.49 0.0100 5.00 .1956 5.56 .1659
Breathless or faint when 
standing
8.41 10.28 .1001 8.87 0.7386 12.99 .0367 12.07 .1693
In all cases, the reference group for hypothesis testing was “No OH.”
Abbreviations: COH, consensus orthostatic hypotension; IDOH, isolated diastolic orthostatic hypotension; ISOH, isolated systolic orthostatic 
hypotension; SDOH, combined systolic and diastolic orthostatic hypotension.
aThese measures exclude 132 men with prevalent atrial fibrillation. 
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participants with prevalent myocardial infarction and stroke were 
excluded (Table 5).
In multiple logistic regression analyses, we calculated the odds 
of consensus OH, and its components, with elevated levels of phos-
phate, IL-6, VWF, D-dimer, hs-troponin T, and NT-proBNP (levels of 
biomarkers were categories into tertiles and “elevated” was defined 
as top tertile vs bottom) (Table 6). Elevated phosphate was statisti-
cally significantly associated with consensus OH and isolated dia-
stolic OH; elevated VWF with consensus OH and isolated systolic 
OH; elevated hs-troponin T with isolated diastolic OH and elevated 
NT-proBNP with combined systolic and diastolic OH. Elevated IL-6 
appeared to be associated with combined systolic and diastolic OH, 
as did elevated D-dimer, but these associations were not statistically 
significant.
4  | DISCUSSION
In this study of older, community-dwelling British men, consensus 
OH was common. The vast majority of men with consensus OH did 
not report symptoms of breathlessness or feeling faint on standing. 
Of the components of consensus OH, isolated systolic OH was most 
common; it was almost three times as prevalent as isolated diastolic 
OH. Men with consensus OH had elevated levels of blood markers 
that are implicated in endothelial dysfunction, vascular calcification, 
myocardial injury, and cardiac stress, compared to men without con-
sensus OH. Our findings are consistent with a previous study report-
ing OH to be associated with a more adverse cardiovascular profile.9
Men with consensus OH were older, had higher blood pressure 
and resting heart rate, compared to those without consensus OH. 
Although smoking and alcohol consumption are known to affect 
blood pressure,36,37 there was no statistically significant difference 
in prevalence of consensus OH among men who were current smok-
ers and those who reported moderate to heavy alcohol consump-
tion. Possible explanations for this include misclassification of men 
with and without OH (repeated measurements of orthostatic blood 
pressure across a period of time (days or weeks) may have permitted 
more accurate classification) and/or the possibility that smoking and 
alcohol consumption may only affect postural blood pressure mea-
surements in the acute period following consumption.
Orthostatic hypotension has been shown to increase risk of car-
diovascular disease, including stroke, heart failure, atrial fibrillation, 
and myocardial infarction.4-7 Our findings highlight the association 
between specific circulating cardiovascular risk markers and OH, 
providing further evidence that OH may be associated with increased 
cardiovascular risk. Our study extends previous research by investi-
gating a wider range of cardiovascular risk markers in an older co-
hort—in whom the burden of OH is greatest—and contrasting the risk 
profile of isolated systolic OH, isolated diastolic OH, and combined 
systolic and diastolic OH; a distinction that has, thus far, been made 
infrequently. The different components of OH may be of different 
prognostic value, with respect to risk of cardiovascular events, falls 
and cognitive function,23,38-40 and the present findings, which show T
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TA B L E  3   Univariate linear regression analysis of the association between cardiovascular risk markers and consensus OH. The values 
presented are means with their standard error
No OH (n = 3079)
Mean (SE)
COH (n = 778)
Mean (SE) P
Metabolic markers
Cholesterol, mmol/L 6.00 (0.02) 6.02 (0.04) .7682
LDL, mmol/L 3.88 (0.02) 3.89 (0.04) .6866
HDL, mmol/L 1.31 (0.01) 1.35 (0.01) .0074
Triglycerides,a  mmol/L 1.63 (1.01) 1.57 (1.02) .0919
Glucose,a  mmol/L 5.87 (1.00) 5.93 (1.01) .2009
Urate, mmol/L 0.38 (<0.01) 0.39 (<0.01) .3278
Inflammatory markers
CRP,a  mg/L 1.70 (1.02) 1.77 (1.04) .3361
IL-6,a  pg/mL 2.39 (1.01) 2.59 (1.02) .0023*
Markers of hemostatis
Fibrinogen,a  g/L 3.16 (1.00) 3.22 (1.01) .0241
VWF, IU/dL 137.07 (0.81) 147.04 (1.74) <.0001*
D-dimer,a  ng/mL 81.45 (1.01) 91.84 (1.03) .0004*
Marker of mineral metabolism
Phosphate, mmol/L 1.15 (<0.01) 1.17 (0.01) .0013*
Markers of cardiac stress and myocardial injury
NT-proBNP,a  pg/mL 91.84 (1.02) 117.92 (1.04) <.0001*
Hs-troponin T,a  pg/mL 11.7 (1.01) 12.68 (1.02) <.0001*
The number of missing values for each variable out of sample size of 3857 was as follows: Cholesterol 12, LDL 67, HDL 35, triglycerides 11, glucose 
13, urate 9, phosphate 31, CRP 31, IL-6 34, fibrinogen 8, VWF 6, D-dimer 9, NT-proBNP 248, hs-troponin T 25.
aGeometric mean (standard error); all other values are the arithmetic mean (standard error). 
*Statistically significant after Bonferroni adjustment (P < .05/14 tested markers, ie, P < .0036). 
TA B L E  4   Multiple linear regression analysis of the association between cardiovascular risk markers, OH and its individual components. 
The values presented are means with their standard error
Blood marker
No OH
(n = 3079)
COH
(n = 778)
P
ISOH
(n = 485)
P
IDOH
(n = 177)
P
SDOH
(n = 116)
PMean (SE) Mean (SE) Mean (SE) Mean (SE) Mean (SE)
IL-6,*,a pg/mL 2.40 (1.01) 2.47 (1.02) .2983 2.40 (1.03) .9916 2.49 (1.05) .4406 2.74 (1.06) .0292
Phosphate, 
mmol/L
1.15 (<0.01) 1.18 (0.01) <.0001* 1.16 (0.01) .0988 1.19 (0.01) .0011* 1.21 (0.01) .0001*
VWF, IU/dL 137.38 (0.80) 145.36 (1.64) <.0001* 144.70 (2.05) .0010* 145.46 (3.39) .0207 148.09 (4.18) .0122
D-dimer,*,a ng/
mL
82.73 (1.01) 86.70 (1.03) .1499 83.92 (1.04) .7102 85.15 (1.06) .6362 102.82 (1.08) .0038
NT-proBNP,*,a 
pg/mL
94.85 (1.02) 101.00 (1.04) .1285 91.86 (1.05) .5219 108.95 (1.08) .0828 136.09 (1.10) .0001*
Hs-troponin 
T,*,a pg/mL
11.72 (1.01) 12.12 (1.02) .0692 12.00 (1.02) .2983 12.42 (1.03) .0983 12.21 (1.04) .3399
Abbreviations: COH, consensus orthostatic hypotension; IDOH, isolated diastolic orthostatic hypotension; ISOH, isolated systolic orthostatic 
hypotension; SDOH, combined systolic and diastolic orthostatic hypotension.
The multiple regression models adjusted for age, body mass index, mean sitting systolic blood pressure, resting pulse, smoking status, alcohol 
consumption, social class, physical activity, presence of prevalent stroke, myocardial infarction, atrial fibrillation, diabetes mellitus, chronic kidney 
disease, chronic obstructive pulmonary disease, and current antihypertensive medication use. In all cases of hypothesis testing, “No OH” was the 
reference group.
aGeometric mean (standard error); all other values are the arithmetic mean (standard error). 
*Statistically significant after Bonferroni adjustment (P < .0036). 
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differing relationships between the components of OH and markers 
of cardiovascular risk, may help explain these differences.
4.1 | OH, endothelial dysfunction, hemostatis, 
vascular calcification, and inflammation
Consensus OH was associated with elevated levels of VWF and 
phosphate. VWF is a glycoprotein involved in hemostasis and cir-
culating levels may reflect both endothelial dysfunction or activa-
tion.13 In a small study of 178 patients with unexplained syncope, 
of whom only 49 had OH, elevated VWF was associated with OH12; 
the present study extends these findings to an older, larger and pre-
dominantly asymptomatic cohort of men. Orthostatic stress may 
trigger the coagulation system by fluid shift and increased intravas-
cular pressures, resulting in endothelial cell activation, as reflected 
by increased VWF.41 Increased concentrations and activity of VWF 
may result in endothelial damage, platelet adhesion, and aggregation 
(thus, hypercoagulability), which may mediate atherogenesis.12 Our 
finding that D-dimer—a marker of activated coagulation—is elevated 
in men with combined systolic and diastolic OH further supports the 
notion that OH may be associated with hypercoagulability, but the 
association between D-dimer and OH was not statistically signifi-
cant after Bonferroni adjustment. We are not aware of findings that 
have previously associated D-dimer and OH.
Phosphate was associated with consensus OH, isolated diastolic 
OH, and combined systolic and diastolic OH. Phosphorus, found 
in the body as phosphate, is an essential mineral. Raised levels of 
TA B L E  5   Multiple linear regression sensitivity analysis of the association between cardiovascular risk markers, OH, and its individual 
components. The values presented are means with their standard error. The sensitivity analysis excluded 352 participants with prevalent 
stroke and/or myocardial infarction
Blood marker
No OH
(n = 2795)
COH
(n = 710)
P
ISOH
(n = 450)
P
IDOH
(n = 155)
P
SDOH
(n = 105)
PMean (SE) Mean (SE) Mean (SE) Mean (SE) Mean (SE)
Phosphate, mmol/L 1.15 (<0.01) 1.18 (0.01) <.0001* 1.17 (0.01) .0341 1.19 (0.01) .0057 1.21 (0.02) .0002*
VWF, IU/dL 135.94 (0.84) 144.48 (1.70) <.0001* 143.37 (2.11) .0012* 146.07 (3.60) .0062 147.00 (4.34) .0128
D-dimer,a  ng/mL 79.90 (1.01) 84.34 (1.03) .1042 82.44 (1.04) .4273 82.38 (1.06) .632 96.75 (1.08) .013
NT-proBNP,a  pg/mL 87.99 (1.02) 92.36 (1.04) .2568 84.94 (1.05) .4909 98.64 (1.09) .1745 121.99 (1.10) .0009*
Abbreviations: COH, consensus orthostatic hypotension; IDOH, isolated diastolic orthostatic hypotension; ISOH, isolated systolic orthostatic 
hypotension; SDOH, combined systolic and diastolic orthostatic hypotension.
The multiple regression models adjusted for age, body mass index, mean sitting systolic blood pressure, resting pulse, smoking status, alcohol 
consumption, social class, physical activity, presence of prevalent atrial fibrillation, diabetes mellitus, chronic kidney disease, chronic obstructive 
pulmonary disease, and current antihypertensive medication use. In all cases of hypothesis testing, “No OH” was the reference group.
aGeometric mean (standard error); all other values are the arithmetic mean (standard error). 
*Statistically significant after Bonferroni adjustment (P < .0036). 
TA B L E  6   Odds of consensus OH, and its components, when levels of cardiovascular risk markers are elevated (the markers were grouped 
into tertiles and “elevated” was defined as top tertile vs bottom tertile)
No OH
(n = 3079)
COH
(n = 778)
ISOH
(n = 485)
IDOH
(n = 177)
SDOH
(n = 116)
Odds ratio (95% Confidence interval)
Phosphate, mmol/L 1.00 1.39 (1.13-1.71) 1.22 (0.95-1.57) 1.53 (1.04-2.25) 2.12 (1.31-3.44)
IL-6, pg/mL 1.00 1.05 (0.84-1.31) 0.97 (0.75-1.27) 1.04 (0.68-1.57) 1.51 (0.89-2.55)
VWF, IU/dL 1.00 1.45 (1.18-1.79) 1.35 (1.05-1.73) 1.38 (0.92-2.08) 2.27 (1.35-3.83)
D-dimer, ng/mL 1.00 1.08 (0.86-1.35) 0.99 (0.75-1.30) 1.22 (0.80-1.86) 1.34 (0.79-2.28)
NT-proBNP, pg/mL 1.00 1.13 (0.88-1.45) 0.97 (0.72-1.30) 1.16 (0.72-1.88) 2.14 (1.14-4.03)
Hs-troponin T, pg/
mL
1.00 1.10 (0.88-1.38) 0.99 (0.76-1.30) 1.69 (1.07-2.65) 0.87 (0.51-1.50)
Abbreviations: COH, consensus orthostatic hypotension; IDOH, isolated diastolic orthostatic hypotension; ISOH, isolated systolic orthostatic 
hypotension; SDOH, combined systolic and diastolic orthostatic hypotension.
The cut-offs for individual tertiles were as follows: Phosphate (mmol/L) tertile 1 (T1) < 1.10, tertile 2 (T2) ≥ 1.10 to <1.22, tertile 3 (T3) ≥ 1.22; VWF 
(IU/dL) T1 < 116, T2 ≥ 116 to <155, T3 ≥ 155, D-dimer (ng/mL) T1 < 58, T2 ≥ 58 to <104, T3 ≥ 104; NT-proBNP (pg/mL) T1 < 59, T2 ≥ 59 to <140, 
T3 ≥ 140, hs-troponin T (pg/mL) T1 < 9.8, T2 ≥ 9.8 to <14.3, T3 ≥ 14.3. The odds ratios were calculated from multiple logistic regression models, 
which adjusted for age, body mass index, mean sitting systolic blood pressure, resting pulse, total cholesterol, smoking status, alcohol consumption, 
physical activity, social class and the presence of prevalent stroke, myocardial infarction, atrial fibrillation, diabetes mellitus, chronic kidney disease, 
and current antihypertensive medication use. In all cases, “No OH” was the reference group for hypothesis testing.
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phosphate are associated with increased risk of cardiovascular dis-
ease.42 We are not aware of phosphate previously being associated 
with OH. However, given that elevated serum phosphate may con-
tribute to vascular calcification43,44 and that hyperphosphatemia, in 
vitro, has been shown to cause endothelial cell apoptosis, which may 
impair endothelial integrity,45 it is biologically plausible that phos-
phate may contribute to OH, through detrimental effects on vas-
cular function. Although the present analysis was cross-sectional, 
and we are unable to comment on temporality based on our results 
alone, recent prospective data in a large cohort have shown OH to 
be associated with carotid intimal thickness and carotid plaque.9 
These are features of atherosclerotic vascular disease, and vascu-
lar calcification is widely used as an indicator of atherosclerosis.46 
Thus, our finding that elevated phosphate is associated with OH is 
consistent with the notion that OH is associated with subclinical car-
diovascular disease.
C-reactive protein is an inflammatory acute phase reactant and 
IL-6 a pro-inflammatory cytokine; both are associated with future 
risk of cardiovascular disease.47 We did not find an association be-
tween CRP and consensus OH, confirming previous findings.48 IL-6 
was associated with consensus OH in a univariate analysis, but this 
association was not statistically significant after adjustment for po-
tential confounders, such as age, body mass index, and co-morbid 
conditions. In a recent, small cross-sectional study of 279 adults re-
ferred to a tertiary syncope unit, there was an association between 
OH and the inflammatory biomarkers midkine, immunoglobulin-like 
transcript 3, and regenerating islet-derived protein 4.11 Thus, the 
potential association between OH and inflammatory biomarkers 
needs to be examined further, particularly because inflammatory 
processes are strongly associated with cardiovascular disease.49 
Further research may clarify whether only particular inflammatory 
mediators are associated with OH or whether the increased risk of 
cardiovascular disease that is associated with OH is independent of 
inflammatory processes.
4.2 | OH, myocardial injury, and cardiac stress
Elevated hs-troponin T, a marker of myocardial injury, was associated 
with isolated diastolic OH, while elevated NT-proBNP, a marker of 
cardiac stress, was associated with combined systolic and diastolic 
OH. These findings may help explain longitudinal findings that have 
(a) associated the diastolic component of OH, but not the systolic 
component, with increased risk of myocardial infarction23 and (b) as-
sociated OH with incident heart failure.4 Most coronary blood flow 
occurs during diastole. Repeated decreases in diastolic blood pres-
sure, as would be expected in people with diastolic OH, may result in 
intermittent episodes of myocardial hypoperfusion,23 leading to my-
ocardial injury, and accounting for the elevated levels of hs-troponin 
T in these people. Longer-term, compensatory structural changes to 
the heart may arise as a result of this increased ischemic burden, and 
subsequent injury, that may be occurring on a microvascular level, 
predisposing to heart failure.
In the Atherosclerosis Risk in Communities Study, detectable 
hs-troponin T was associated with systolic OH, but not diastolic OH, 
while isolated systolic OH and isolated diastolic OH were both as-
sociated with elevated NT-proBNP.9 This is in contrast to the pres-
ent study in which hs-troponin T was more closely associated with 
the diastolic component of OH, rather than the systolic component, 
and NT-proBNP was more strongly associated with combined sys-
tolic and diastolic OH. These differences may reflect age differences 
in the two cohorts, as participants in the Atherosclerosis Risk in 
Communities Study cohort were, on average, 15 years younger than 
that those in the present study.
4.3 | Strengths and limitations
Strengths of our study include the wide range of biomarkers stud-
ied and that we examined the components of OH. However, our 
cohort consisted exclusively of men who were almost entirely of 
white European ethnicity, limiting the external validity of our find-
ings. Although we examined the components of OH, the sample 
in each group was relatively small, raising the possibility of type II 
errors; the confidence intervals in Table 6 provide insights into the 
strengths of associations which could not be excluded. Likewise, 
although we adjusted for multiple statistical comparisons using the 
Bonferroni method, this conservative adjustment method may have 
also predisposed to type II errors. Furthermore, there were multiple 
differences between several baseline characteristics among people 
with and without OH and we are unable to exclude the possibility of 
residual confounding.
We did not have supine and standing measurements of blood 
pressure and instead used sitting and standing measurements to 
define OH as per thresholds that are usually applied to supine 
and standing measurements. Although supine-to-standing mea-
surements are more frequently employed in research settings, 
sitting-to-standing measurements are often used in clinical prac-
tice for convenience. The decrease in blood pressure that occurs 
when changing position from supine to standing can be expected 
to be greater than that which occurs when changing position from 
sitting to standing because the shift in fluid is greater in the first 
scenario. It is unknown whether lower thresholds should be used 
to diagnose OH based on sitting-to-standing blood pressure mea-
surements, compared to supine-to-standing measurements. If this 
were the case, then it is likely that our measures of risk are under-
estimates, as our study would have misclassified people who truly 
had OH as not having it. The lack of supine blood pressure mea-
surements means we are unable to exclude supine hypertension 
as a confounding factor. Furthermore, we did not have blood pres-
sure measurements beyond three minutes of standing and would 
have misclassified men who developed OH after a prolonged pe-
riod of standing. It has previously been suggested that specific or-
thostatic changes in heart rate, if they accompany OH, can provide 
insight into whether the cause of OH is neurogenic or non-neu-
rogenic.50 Based on our findings alone, which do not account for 
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orthostatic changes in heart rate, we are unable to comment on 
whether the associations of some markers of cardiovascular risk 
may differ between different causes of OH.
Finally, this analysis was cross-sectional. We are unable to 
comment on temporal relationships: While OH appears to be asso-
ciated with some markers of cardiovascular risk, we are unable to 
conclude definitively whether OH is simply a biomarker of vascu-
lar risk and cardiac dysfunction or if OH induces endothelial dys-
function, vascular calcification, myocardial injury, and/or cardiac 
stress.
5  | CONCLUSIONS
In older men, OH is associated with some cardiovascular risk mark-
ers implicated in endothelial dysfunction, vascular calcification, 
myocardial injury, and cardiac stress. The markers are differen-
tially distributed among the components of OH, suggesting the 
components may have different etiologies. Our findings support 
to the hypothesis that OH is associated with increased cardio-
vascular risk. They may help explain findings from observational 
studies that have shown OH to be associated with increased risk 
of cardiovascular disease, including stroke, myocardial infarction, 
and heart failure. They support the notion that patients with OH 
should have their cardiovascular risk assessed. Further, prospec-
tive work should continue to examine the components of OH and 
control for markers of cardiovascular risk when attempting to de-
lineate a temporal relationship between OH and cardiovascular 
morbidity.
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